Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary GlobeNewswire - Thu Jan 8, 5:00PM CST

Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage...

ANAB : 48.13 (-1.85%)
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Tue Jan 6, 3:15PM CST

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 48.13 (-1.85%)
A colorful concept image of a scoring system_ Image by Who is Danny via Shutterstock_
This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving Barchart - Fri Dec 19, 2025

AnaptysBio (ANAB) has surged 227% over the past year, hitting a 5-year high. Shares have strong technical momentum and a 100% “Buy” opinion from Barchart. Analyst sentiment remains bullish, but Wall...

ANAB : 48.13 (-1.85%)
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis PR Newswire - Mon Dec 15, 2025

WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration...

ANAB : 48.13 (-1.85%)
VNDA : 7.44 (+0.40%)
Anaptys Announces Participation in December Investor Conferences GlobeNewswire - Tue Nov 25, 2025

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 48.13 (-1.85%)
Anaptys Announces $100 Million Stock Repurchase Plan GlobeNewswire - Fri Nov 21, 2025

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its...

ANAB : 48.13 (-1.85%)
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary GlobeNewswire - Fri Nov 21, 2025

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a...

ANAB : 48.13 (-1.85%)
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis GlobeNewswire - Mon Nov 10, 2025

Rosnilimab was safe and well tolerated with similar adverse event rates vs . placebo Observed expected pharmacology, including ~90% depletion of pathogenic T cells, however lack of adequate efficacy...

ANAB : 48.13 (-1.85%)
Anaptys Announces Participation in November Investor Conferences GlobeNewswire - Tue Nov 4, 2025

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel...

ANAB : 48.13 (-1.85%)
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire - Tue Nov 4, 2025

Announced intent to separate biopharma operations from substantial royalty assets by YE 2026 Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on...

ANAB : 48.13 (-1.85%)

Barchart Exclusives

Should You Buy Dividend-Paying Gold Stocks as Trump Makes Them ‘Great Again’? Barchart - Tue Jan 13, 6:30PM CST
Gold stocks have soared over the last year amid the rally in gold prices. Miners are paying handsome dividends as their cash flows have tracked gold prices higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot